Could SER-109 be an Answer for Recurrent C.Difficile Infection?
Evidence Based Medicine presented by InpharmD™ · InpharmD™
February 22, 20225m 11s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment.